BRPI0722054A2 - Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. - Google Patents
Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.Info
- Publication number
- BRPI0722054A2 BRPI0722054A2 BRPI0722054-5A2A BRPI0722054A BRPI0722054A2 BR PI0722054 A2 BRPI0722054 A2 BR PI0722054A2 BR PI0722054 A BRPI0722054 A BR PI0722054A BR PI0722054 A2 BRPI0722054 A2 BR PI0722054A2
- Authority
- BR
- Brazil
- Prior art keywords
- calcineurin inhibitor
- analylogal
- tacrolimus
- analogue
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88230606P | 2006-12-28 | 2006-12-28 | |
US94037507P | 2007-05-25 | 2007-05-25 | |
US95319207P | 2007-07-31 | 2007-07-31 | |
PCT/US2007/088827 WO2008083160A2 (en) | 2006-12-28 | 2007-12-26 | Methods and compositions for therapeutic treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0722054A2 true BRPI0722054A2 (pt) | 2014-04-01 |
Family
ID=39584863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0722054-5A2A BRPI0722054A2 (pt) | 2006-12-28 | 2007-12-26 | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080161248A1 (pt) |
EP (1) | EP2068865A4 (pt) |
JP (1) | JP2010514790A (pt) |
KR (1) | KR20090094090A (pt) |
CN (1) | CN101573109A (pt) |
AU (1) | AU2007339883A1 (pt) |
BR (1) | BRPI0722054A2 (pt) |
CA (1) | CA2673863A1 (pt) |
IL (1) | IL198723A0 (pt) |
MX (1) | MX2009006958A (pt) |
WO (1) | WO2008083160A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009018338A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
WO2009158031A2 (en) * | 2008-06-27 | 2009-12-30 | Limerick Biopharma, Inc. | Methods and compositions for therapeutic treatment |
JP5655243B2 (ja) * | 2009-10-19 | 2015-01-21 | 国立大学法人 熊本大学 | インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤 |
WO2011091247A1 (en) * | 2010-01-21 | 2011-07-28 | Indiana University Research And Technology Corporation | Mixed aminal pharmaceutical compositions and uses thereof |
CN102633850A (zh) * | 2010-08-16 | 2012-08-15 | 江西山香药业有限公司 | 野漆树苷的提取方法及其制备药物用途 |
CN102716118A (zh) * | 2011-03-29 | 2012-10-10 | 复旦大学 | 金雀异黄素及其衍生物在制备催眠类药物中的用途 |
CN102793712A (zh) * | 2012-09-07 | 2012-11-28 | 天津医科大学 | 白杨素在制备治疗自身免疫及炎症性疾病药物方面的应用 |
FR2999934B1 (fr) * | 2012-12-21 | 2015-02-20 | Servier Lab | Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane |
KR101694879B1 (ko) | 2014-08-01 | 2017-01-12 | 주식회사 인트론바이오테크놀로지 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
CN104535774B (zh) * | 2015-01-16 | 2017-04-19 | 中国药科大学 | 一种炎性肠病状态下药物敏感性的新检测指标及其在药物治疗方案设计中的应用 |
KR101751486B1 (ko) * | 2016-03-02 | 2017-06-28 | 광주과학기술원 | BKCa 채널 활성화용 조성물 |
CN111450231B (zh) * | 2020-02-12 | 2023-10-31 | 南昌大学第一附属医院 | 靛玉红衍生物在制备他克莫司或环孢素的增效剂药物中的用途 |
WO2023192259A1 (en) * | 2022-03-28 | 2023-10-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synergy for increasing insulin sensitivity |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
GB2222770B (en) * | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
US5643901A (en) * | 1990-06-11 | 1997-07-01 | Fujisawa Pharmaceutical Co., Ltd. | Medicament for treating idiopathic thrombocytopenic purpura |
US5348966A (en) * | 1990-10-24 | 1994-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds |
US5817333A (en) * | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
JPH06345646A (ja) * | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
US6362160B1 (en) * | 1993-06-30 | 2002-03-26 | The Johns Hopkins University School Of Medicine | Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke and neurodegenerative diseases |
US6022852A (en) * | 1993-10-22 | 2000-02-08 | Hexal Ag | Pharmaceutical composition containing cyclosporin A |
KR20000076018A (ko) * | 1997-03-07 | 2000-12-26 | 아키라 하야시 | 세균의 균체 성분을 유효 성분으로 하는 암 면역 요법제 |
AU748334B2 (en) * | 1997-10-16 | 2002-05-30 | Board Of Regents, The University Of Texas System | Models and treatments for cardiac hypertrophy in relation with NF-AT3 function |
US6013621A (en) * | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
PT1056454E (pt) * | 1998-02-23 | 2003-08-29 | Fujisawa Pharmaceutical Co | Utilizacao de compostos macrolido para o tratamento do glaucoma |
AUPP223198A0 (en) * | 1998-03-06 | 1998-04-02 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US6458777B1 (en) * | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
KR100505464B1 (ko) * | 1998-03-26 | 2005-08-04 | 후지사와 야꾸힝 고교 가부시키가이샤 | 서방성 제제 |
WO1999051215A2 (en) * | 1998-04-06 | 1999-10-14 | Fujisawa Pharmaceutical Co., Ltd. | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
AUPP584198A0 (en) * | 1998-09-14 | 1998-10-08 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US6864232B1 (en) * | 1998-12-24 | 2005-03-08 | Sucampo Ag | Agent for treating visual cell function disorder |
CA2364257A1 (en) * | 1999-03-11 | 2000-09-14 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparations |
WO2000071546A1 (en) * | 1999-05-25 | 2000-11-30 | Fujisawa Pharmaceutical Co., Ltd. | Method for separating analogous organic compounds |
WO2001048154A1 (fr) * | 1999-12-28 | 2001-07-05 | Toyoshima, Kumao | Agent de maturation pour cellules dendritiques immatures |
US6489640B1 (en) * | 2000-10-06 | 2002-12-03 | National Semiconductor Corporation | Integrated circuit with fuse element and contact pad |
US20040091477A1 (en) * | 2001-05-08 | 2004-05-13 | David Haines | Immunosuppresive compositions |
WO2003009859A1 (fr) * | 2001-07-19 | 2003-02-06 | Azuma, Ichiro | Immunotherapie pour humains |
US7169763B2 (en) * | 2002-02-22 | 2007-01-30 | Oliver Yoa-Pu Hu | Cytochrome P450 3A inhibitors and enhancers |
GB2391473B (en) * | 2002-08-02 | 2004-07-07 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
DE10240923A1 (de) * | 2002-09-02 | 2004-03-04 | Merck Patent Gmbh | Flavonoid-Derivate zur Ekzem-Behandlung |
EP1838296B1 (en) * | 2004-10-20 | 2012-08-08 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
CN101137639B (zh) * | 2005-03-11 | 2012-05-23 | 霍华德弗洛里生理医学实验研究所 | 类黄酮化合物及其用途 |
US20080153819A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor |
-
2007
- 2007-12-26 CA CA002673863A patent/CA2673863A1/en not_active Abandoned
- 2007-12-26 BR BRPI0722054-5A2A patent/BRPI0722054A2/pt not_active IP Right Cessation
- 2007-12-26 EP EP07869911A patent/EP2068865A4/en not_active Withdrawn
- 2007-12-26 WO PCT/US2007/088827 patent/WO2008083160A2/en active Application Filing
- 2007-12-26 CN CNA2007800485119A patent/CN101573109A/zh active Pending
- 2007-12-26 MX MX2009006958A patent/MX2009006958A/es not_active Application Discontinuation
- 2007-12-26 US US11/964,377 patent/US20080161248A1/en not_active Abandoned
- 2007-12-26 JP JP2009544248A patent/JP2010514790A/ja not_active Withdrawn
- 2007-12-26 KR KR1020097012060A patent/KR20090094090A/ko not_active Application Discontinuation
- 2007-12-26 AU AU2007339883A patent/AU2007339883A1/en not_active Abandoned
-
2009
- 2009-05-12 IL IL198723A patent/IL198723A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2068865A2 (en) | 2009-06-17 |
AU2007339883A1 (en) | 2008-07-10 |
WO2008083160A3 (en) | 2009-04-16 |
EP2068865A4 (en) | 2011-08-10 |
WO2008083160A2 (en) | 2008-07-10 |
CA2673863A1 (en) | 2008-07-10 |
KR20090094090A (ko) | 2009-09-03 |
JP2010514790A (ja) | 2010-05-06 |
US20080161248A1 (en) | 2008-07-03 |
IL198723A0 (en) | 2010-02-17 |
MX2009006958A (es) | 2009-07-09 |
CN101573109A (zh) | 2009-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0722054A2 (pt) | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
WO2007103719A3 (en) | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | |
NO20083202L (no) | ANG2- og VEFG-inhibitorkombinasjoner | |
EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
WO2008003007A3 (en) | Compositions and methods for treating parasitic infections | |
CL2007002261A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. | |
BRPI0906549A2 (pt) | Bandagens médicas com válvulas e kits contendo as mesmas. | |
EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
EA200802332A1 (ru) | Пирролопиримидины и их применение | |
CL2007001911A1 (es) | Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum, en donde la composicion carece de cualquier otro componente proteico del complejo para tratar una afeccion asociada con la inervacion colinergica muscular hiperactiva | |
BRPI0918139A2 (pt) | composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos e uso | |
BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
CR10245A (es) | "nuevas combinaciones terapéuticas para el tratamiento de la depresión" | |
CL2007003038A1 (es) | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. | |
HK1137352A1 (en) | Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent | |
BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
DK2035006T3 (da) | Anvendelse af allopurinol til behandling af palmar-plantar erythrodysestesi | |
CL2007003480A1 (es) | Compuestos derivados de tiazolo[5,4-c]piridin-4-ona sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de enfermedades relacionadas con la obesidad, como trastornos de la alimentacion, diab | |
NO20082636L (no) | Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A E 6A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A E 12A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |